Larysa Skivka




Larysa Skivka

POSITION
Head of the Department of Microbiology and General Immunology

WORK EXPERIENCE
1988–1992
Research Assistant
R.E.Kavetsky Institute of Experimental Pathology, Oncology and Radiobiology, National Academy of Sciences, Kyiv (Ukraine)

19921998
Researcher
R.E.Kavetsky Institute of Experimental Pathology, Oncology and Radiobiology, National Academy of Sciences, Kyiv (Ukraine)

19982002
Postdoc
R.E.Kavetsky Institute of Experimental Pathology, Oncology and Radiobiology, National Academy of Sciences, Kyiv (Ukraine)

2002-2009
Assistant lecturer
Taras Shevchenko National University of Kyiv, Kyiv (Ukraine)

20022009
Professor assistant
Taras Shevchenko national University of Kyiv, Kyiv (Ukraine)

2013Present
Head of the Department of Microbiology and General Immunology
Taras Shevchenko National University of Kyiv, Kyiv (Ukraine)

EDUCATION AND TRAINING

1988
MSc
Taras Shevchenko National University of Kyiv, Kyiv (Ukraine)

1995
PhD
R.E.Kavetsky Institute of Experimental Pathology, Oncology and Radiobiology, National Academy of Sciences, Kyiv (Ukraine)

2013
ScD
Taras Shevchenko National University of Kiev, Kyiv (Ukraine)

Phagocyte metabolic polarization

Research Fields:
Immunology
Microbiology

Previous and Current Research

  • Bacterial immunomodulation;
  • Cancer immunology and immunoadjuvant therapy;
  • Phagocyte metabolic polarization.

Our group is focused on the investigation of mechanisms and triggers of phagocyte (tissue and circulating phagocytes, mononuclear and polymorphonuclear cells) metabolic polarization (see fig.1). We pay great attention to the evaluation of the role of phagocyte metabolic polarization in the pathogenesis of inflammatory disorders (inflammatory diseases including colitis, acute pancreatitis, obesity, neurodegenerative disorders, cancer etc). Applied aspect of our research is to use the estimation of phagocyte metabolic polarization (alone and/or in combination with other biomarkers) for the diagnostics of inflammatory disorders, the prognosis of inflammatory disease course and prediction of the therapeutic efficacy of immunomodulating and anti-inflammatory agents.


Future Projects and Goals

  • Microglia metabolic reprogramming in the treatment of malignant glioma.
  • Preclinical testing and/or experimental screening aimed to search for new anti-inflammatory, anticancer, immunomodulating as well as hepatoprotective agents.
  • Development of complex methodological strategy with the use of the analysis of phagocyte functional polarization for the diagnostics and monitoring of inflammatory disorders as well as for the evaluation of the effectiveness of the treatments for inflammatory diseases.

Methodological and Technical Expertise

  • Common laboratory animal handling as well as intracranial diagnostics, and therapeutic manipulations with the use of developed intracranial drug delivery device (patent of Ukraine);
  • Allograft mouse tumor systems including experimental (murine) model of directed tumor metastasizing in the liver (patent of Ukraine N85641), see fig.2;

  • Circulating and resident tissue phagocyte isolation, isolation and culture of bone marrow-derived macrophages, in vitro generation of M1 and M2 polarized macrophages;
  • Functional assays (phagocytes): colorimetric methods, flow cytometry etc.
  • Additional methods (ELISA (biological fluids and tissue lysates), MTT-test, polyclonal antibodies preparation, immunocytochemistry, serological assays, PCR, SDS-PAGE etc.).

Selected Publications


Skivka LM, Horbyk HV, Fedorchuk OH, Pozur VV.
Tumor-Associated Macrophages in the Prospect of Development of Targeted Anticancer Therapy
Cytology and Genetics. - 2009, 43(4), P. 283–292.

Skivka L, Susak Y, Trompak O, Kudryavets Y, Bezdeneznikh N, Semesiuk N, Lykhova O.
The effect of monotherapy and combined therapy with NSC-631570 (ukrain) on growth of low- and high-metastasizing B16 melanoma in mice
Journal of Oncology Farmacy Practice. 2011, 17(4), P.339-350.

Fedorchuk OG, Pyaskovskaya OM, Skivka LM, Gorbik GV, Trompak OO, Solyanik GI.
Paraneoplastic syndrome in mice bearing high-angiogenic variant of Lewis lung carcinoma: Relations with tumor derived VEGF
Cytokine. 2012, 57(1), P.81-88.

Skivka LM, Fedorchuk OG, Rudyk MP, Pozur VV, Khranovska NM, Grom MY, Nowicky JW.
Antineoplastic drug NSC631570 modulates functions of hypoxic macrophages
Cytology and Genetics. - 2013, 47(5), P.318-328.

Skivka LM, Fedorchuk OG, Susak YM, Susak MY, Malanchuk OM, Rudyk MP, Nowicky YW.
Physical activity interferes with the immunomodulatory effect of the antineoplastic drug NSC631570
Current Pharmaceutical Biotechnology. 2015, 15(1), P.49-59.

Prylutska SV, Skivka LM, Didenko GV, Prylutskyy YI, Evstigneev MP, Potebnya GP, Panchuk RR, Stoika RS, Ritter U, Scharff P.
Complex of C60 Fullerene with Doxorubicin as a Promising Agent in Antitumor Therapy
Nanoscale Res Lett. 2015,10(1):499. doi: 10.1186/s11671-015-1206-7.

Skivka LM, Fedorchuk OG, Khranovska NM, Rudyk MP, Opeida IV.
Diurnal variation in functional reserve and metabolic polarization of circulating monocytes in healthy men
European J. of Clinical Investigation. 2015, 45, P.49-52.

Iaroslav Susak, Larysa Skivka, Olexander Tkachenko, Igor Khomenko, Olexander Dyrda
Assessment of circulating phagocyte functional state for the prediction of suppurative complications in patients with acute necrotizing pancreatitis
Pancreatology. 2015, 15(3) Supplement, S6, DOI:

Sydor R.I., Khranovska N.M., Skachkova O.V., Skivka L.M.
The effect of perioperative analgesic drugs omnopon and dexketoprofen on the functional activity of immune cells in murine model of tumor surgery
Ukrainian Biochemical Journal. 2016, 88 (4), P. 29-36.

Mariia Rudyk, Olexander Fedorchuk, Yaroslav Susak, Yaroslav Nowicky, Larysa Skivka
Introduction of antineoplastic drug NSC631570 in an inpatient and outpatient setting: Comparative evaluation of biological effects
Asian Journal of Pharmaceutical Sciences. 2016, 11, Issue 2, . 308317.

Contacts


realmed@i.com.ua